Valeant Opts For Viramidine Dosing Change After Phase III Stumble
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Valeant's analyses of the pivotal VISER1 trial support a change to weight-based dosing of the hepatitis C agent Viramidine, Chief Scientific Officer Kim Lamon said during a teleconference to discuss the trial's mixed results